Trials / Recruiting
RecruitingNCT06632093
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
Hepatic Arterial Infusion Chemotherapy in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced Hepatocellular Carcinoma After the Failure of Systemic Therapy Recommended by BCLC
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 84 (estimated)
- Sponsor
- First Hospital of China Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.
Conditions
- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Hepatic Arterial Infusion Chemotherapy
- Lenvatinib
- PD-1
- Systemic Therapy
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | hepatic artery infusion chemotherapy | Hepatic arterial infusion chemotherapy including FOLFOX and RALOX |
| DRUG | Lenvatinib + PD-1 monoclonal antibody | PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab |
Timeline
- Start date
- 2024-09-16
- Primary completion
- 2025-09-30
- Completion
- 2025-12-30
- First posted
- 2024-10-08
- Last updated
- 2024-10-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06632093. Inclusion in this directory is not an endorsement.